Massive GIST registry aims to unlock secrets of rare cancer
NCT ID NCT07697248
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study is a patient registry for people diagnosed with gastrointestinal stromal tumor (GIST). It collects detailed information about participants' health, treatments, and outcomes over time. The goal is to help researchers better understand the disease, track how patients fare, and ultimately improve care for everyone with GIST.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help researchers better understand GIST, identify effective treatments, and improve patient care.
- What could go wrong
- This is an observational registry, not a treatment trial. It collects data but does not test any intervention, so direct benefits to participants are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2013
- Expected to finish
-
Dec 2099
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Gastrointestinal Stromal Tumor diagnosis
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Gastrointestinal Stromal Tumor diagnosis 2. Provide written and informed consent Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastrointestinal stromal tumor (GIST) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Life Raft Group
RECRUITINGWayne, New Jersey, 07470, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a coordinated care team reduce severe side effects in older cancer patients?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Metabolic MRI may reveal tumor response to GIST drug in weeks, not months
- Can a targeted pill shrink a rare, Treatment-Resistant stomach cancer?
- Blood test may guide cancer care without biopsy